Literature DB >> 17010873

Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones.

Guy Kleinmann1, David J Apple, Jesse Chew, Brian Hunter, Scott Stevens, Scott Larson, Nick Mamalis, Randall J Olson.   

Abstract

PURPOSE: To evaluate the ability and safety of a hydrophilic acrylic intraocular lens (IOL) as a drug-delivery system for commercially available gatifloxacin and moxifloxacin.
SETTING: David J. Apple, MD, Laboratories for Ophthalmic Research, John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah, USA.
METHODS: Thirty rabbits were divided into 2 similar groups. In Group A (15 rabbits, 30 eyes), hydrophilic acrylic IOLs (C-flex, Rayner Intraocular Lenses, Ltd.) presoaked for 24 hours in commercially available solutions of gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL were implanted after evacuation of the crystalline lens. Group B (15 rabbits, 30 eyes) had topical preoperative and postoperative cataract prophylaxis with gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL; IOLs that were not presoaked were also implanted after evacuation of the crystalline lenses. In both groups, aqueous humor samples were taken 4, 8, or 12 hours after IOL implantation (5 eyes at each time point) to determine the antibiotic concentrations. Clinical examinations were performed 24 hours postoperatively.
RESULTS: The antibiotic concentrations in Group A (presoaked IOLs) were statistically significantly higher than those in Group B (topical) for both antibiotics in all postoperative samples except moxifloxacin at 12 hours. In both groups, there was no statistically significant difference between the concentrations of the 2 antibiotics. No eye showed signs of clinical toxicity.
CONCLUSION: Results show the C-flex IOL is a safe and effective drug-delivery system for fourth-generation fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010873     DOI: 10.1016/j.jcrs.2006.04.033

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  8 in total

1.  Sustained-release celecoxib from incubated acrylic intraocular lenses suppresses lens epithelial cell growth in an ex vivo model of posterior capsule opacity.

Authors:  Jennifer L Davis; Na Young Yi; Jacklyn H Salmon; Anna N Charlton; Carmen M H Colitz; Brian C Gilger
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-28       Impact factor: 2.671

Review 2.  Hydrogel-based ocular drug delivery systems: Emerging fabrication strategies, applications, and bench-to-bedside manufacturing considerations.

Authors:  Remy C Cooper; Hu Yang
Journal:  J Control Release       Date:  2019-05-22       Impact factor: 9.776

3.  Effect of delivery of MMP inhibitors from PDMS as a model IOL material on PCO markers.

Authors:  Diana Morarescu; Judy A West-Mays; Heather D Sheardown
Journal:  Biomaterials       Date:  2009-12-22       Impact factor: 12.479

4.  Sustained Antibiotic-Eluting Intra-Ocular Lenses: A New Approach.

Authors:  Dulcia W N Tan; Soo Ghim Lim; Tina T Wong; Subbu S Venkatraman
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

5.  Diffusion-Based Design of Multi-Layered Ophthalmic Lenses for Controlled Drug Release.

Authors:  Andreia F R Pimenta; Ana Paula Serro; Patrizia Paradiso; Benilde Saramago; Rogério Colaço
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

6.  Physicochemical and surface properties of acrylic intraocular lenses and their clinical significance.

Authors:  Gyeong Bok Jung; Kyung-Hyun Jin; Hun-Kuk Park
Journal:  J Pharm Investig       Date:  2017-03-27

Review 7.  Drug-Eluting Intraocular Lenses.

Authors:  Clara González-Chomón; Angel Concheiro; Carmen Alvarez-Lorenzo
Journal:  Materials (Basel)       Date:  2011-11-01       Impact factor: 3.623

Review 8.  A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications.

Authors:  Ioanna Mylona; Ioannis Tsinopoulos
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.